Pharmacokinetics of intravenous, intraperitoneal, and subcutaneous recombinant erythropoietin in patients on CAPD. A rationale for treatment.
Macdougall
I C
IC
KRUF Institute of Renal Disease, University of Wales College of Medicine, Royal Infirmary, Cardiff, UK.
Roberts
D E
DE
Neubert
P
P
Dharmasena
A D
AD
Coles
G A
GA
Williams
J D
JD
D000328:Adult; D000368:Aged; D000740:Anemia / Q000150:complications / Q000188:drug therapy; D001682:Biological Availability; D002986:Clinical Trials as Topic; D004921:Erythropoietin / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D007674:Kidney Diseases / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory
D004921:Erythropoietin